Millennium Management’s enGene Therapeutics ENGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$363K Sell
181,619
-785,008
-81% -$1.45M ﹤0.01% 5220
2026
Q2
$1.67M Buy
966,627
+6,946
+0.7% +$28.3K ﹤0.01% 3957
2026
Q1
$6.54M Sell
959,681
-539,839
-36% -$4.81M ﹤0.01% 2629
2025
Q4
$13.5M Buy
1,499,520
+1,479,018
+7,214% +$11.9M 0.01% 1949
2025
Q3
$140K Buy
20,502
+7,472
+57% +$34.1K ﹤0.01% 5636
2025
Q2
$47.4K Buy
+13,030
New +$48.9K ﹤0.01% 5623

Other funds holding ENGN

Millennium Management's ENGN Position: Q3 2026 in Review

Millennium Management reduced its enGene Therapeutics (ENGN) stake by 81% in Q3 2026, selling an estimated $1.45M and leaving 181,619 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #5220.

Millennium Management first reported a position in ENGN in Q2 2025 and has held it in 6 quarters since. The position peaked at $13.5M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • Millennium Management held 181,619 shares of enGene Therapeutics worth $363K as of Q3 2026.
  • Millennium Management sold 785,008 enGene Therapeutics shares in Q3 2026, an estimated $1.45M.
  • enGene Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #5220 holding.
  • Millennium Management first reported a position in enGene Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Millennium Management's enGene Therapeutics position peaked at $13.5M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.